Raloxifene as a treatment for cognition in women with schizophrenia: the influence of menopause status

Cognitive problems are a core feature of schizophrenia, with up to 80% patients showing significant impairment (Keefe and Fenton, 2007). Cognitive deficits are closely aligned with functional outcome and present a significant obstacle in the recovery process (Green, 1996). Current treatment options do not successfully ameliorate cognitive impairments (Green, 2006; Minzenberg and Carter, 2012). The areas of neurocognition that are primarily impaired include attention, working memory, memory as well as executive functioning skills, such as decision making, inhibition and planning (Minzenberg and Carter, 2012).
Source: Psychoneuroendocrinology - Category: Psychiatry Authors: Source Type: research